tradingkey.logo

New Clinical Data Highlights Caplyta® (Lumateperone) As A Promising Option For Achieving Remission In Adults With Major Depressive Disorder

ReutersJan 16, 2026 1:02 PM

- Johnson & Johnson JNJ.N:

  • NEW CLINICAL DATA HIGHLIGHTS CAPLYTA® (LUMATEPERONE) AS A PROMISING OPTION FOR ACHIEVING REMISSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

  • J&J - 65% REACHED REMISSION WITH CAPLYTA, 43% SUSTAINED RELIEF IN SIX MONTHS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI